Erlotinib hydrochloride

descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 2005Publisher:Springer Science and Business Media LLCJournal:Nature Reviews Drug Discovery, volume 4, pages S14-S15 (issn: 1474-1776, eissn: 1474-1784,

Copyright policy )

Authors: Jonathan Dowell; John D. Minna; Peter Kirkpatrick;

doi: 10.1038/nrd1730 , 10.1038/nrd1612

pmid: 15962526

Erlotinib hydrochloride

- Summary
- Subjects
- Metrics

Abstract

Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.

Related Organizations

The University of Texas Southwestern Medical Center
United States

Keywords

ErbB Receptors, Clinical Trials as Topic, Erlotinib Hydrochloride, Lung Neoplasms, Treatment Outcome, Carcinoma, Non-Small-Cell Lung, Quinazolines, Humans, Antineoplastic Agents

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	222
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 1%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 1%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%